Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Synthetic Secretin (ChiRhoStim) vs Vosoritide (Voxzogo)
An educational, source-based comparison of Synthetic Secretin (ChiRhoStim) and Vosoritide (Voxzogo) — how each peptide works, what it's researched for, and what to know before going deeper.
27-amino-acid peptide used to stimulate pancreatic secretions for diagnosis.
Synthetic human secretin that stimulates pancreatic bicarbonate, fluid secretion, and gastrin release — used diagnostically for pancreatic function, gastrinoma evaluation, and ERCP facilitation.
- Pancreatic function testing
- Gastrinoma (Zollinger-Ellison) diagnosis
- ERCP facilitation
- • FDA-approved.
- • Single diagnostic dose; minimal adverse effects.
C-type natriuretic peptide analog for achondroplasia.
Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.
- Achondroplasia in children ≥5 years (now ≥4 months)
- • FDA-approved.
- • Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Synthetic Secretin (ChiRhoStim) | Secretin stimulation test for gastrinoma | Gastroenterology | 1989 | Established as gold standard provocative test. |
| Vosoritide (Voxzogo) | Vosoritide Phase 3 trial | Lancet | 2020 | Increased annualized growth velocity vs placebo in children with achondroplasia. |
Side-effect & safety grid
- FDA-approved.
- Single diagnostic dose; minimal adverse effects.
- FDA-approved.
- Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Synthetic Secretin (ChiRhoStim) vs Vosoritide (Voxzogo) — Key differences
- Class: Synthetic Secretin (ChiRhoStim) is classified as Diagnostic · Gastroenterology, while Vosoritide (Voxzogo) is CNP Analog · Skeletal Growth.
- Primary research focus: Synthetic Secretin (ChiRhoStim) — pancreatic function testing; Vosoritide (Voxzogo) — achondroplasia in children ≥5 years (now ≥4 months).
- Tag: FDA-Approved · Diagnostic vs FDA-Approved · Genetic.